sorry the better way to phrase the above is that in a burgeoning growing sector; the FDA AAV risk workshop catalyst creates a hard fork to do what’s best for the patient, their risk of even consenting to your trial may no longer be ethical, as the unknown harm across time horizon is too great.
We need to be aware of a byproduct burden; will greater endpoint safety scrutiny be required of RNA therapeutics also?
in summary, new cash should find alternative safer delivery non AAV delivery pathways, and existing sunk assets (with potentiallyhuge unspent cash warchests) should assess alternatives to AAV.
given PYC is now positioning as having two asset categories; ie a dual platform:
1) VP-001, VP-002, CNS-001, and more to come soon 2) Delivery platform
One would conclude that PYC current market cap is at a trading at a steep discount on an NPV assessment of 1) cash flows.
An investor today, is essentially getting 1) for cheap and 2) for free, when in fact 2) could be worth more than 1) in the right time and place.
PYC Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)